Literature DB >> 17707650

Primary lung cancer and extrapulmonary malignancy.

Hans-Stefan Hofmann1, Heinz Neef, Peter Schmidt.   

Abstract

OBJECTIVE: The incidence of second primary malignancies seems to be increasing. The aim of this study was to investigate the incidence, treatment and outcome for patients with second primary lung cancer (SPLC).
METHODS: Between January 1996 and December 2005, 163 patients with SPLC, occurring after an extrapulmonary malignancy, were recruited by the Tumor Center of Halle (Saale), which represents a region of nearly 1.0 million inhabitants in Germany. The SPLCs were treated under curative aim (n=59), with palliative intend (n=76) or best supportive care (n=28).
RESULTS: The incidence of SPLC was 1.6 per 100,000 inhabitants. The localization of the first tumor differed depending on the sex of the patients. The actuarial 5-year survival rate of all patients was 12.7% (median survival time 11.4 months). Univariate analysis revealed treatment strategy as a prognostic factor (p=0.0001). Patients with SPLC having undergone curative treatment turned out to have the best prognosis (median survival: 31.0 months). The Cox proportional hazards model demonstrated that only TNM-staging system was a multivariate and significant independent prognostic predictor for overall survival. The method of surgery, standard lung resection (e.g. lobectomy) versus limited resection had no considerable influence on overall survival (p=0.22), respectively recurrence-free survival (p=0.55).
CONCLUSIONS: In cases of operability, standard resection must be the method of choice, because of its best survival rates. The results support the demand of an exact and short-term oncological care system to detect early stages of SPLC for patients operated upon for tumors at different sites.

Entities:  

Mesh:

Year:  2007        PMID: 17707650     DOI: 10.1016/j.ejcts.2007.06.024

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Lung cancer patients with a previous extra-pulmonary malignancy should not be considered homogeneous: a clinicopathological analysis of 3530 surgical cases.

Authors:  X-L Hu; S-T Xu; X-C Wang; D-N Hou; C Bao; D Yang; Y-L Song
Journal:  Clin Transl Oncol       Date:  2018-08-21       Impact factor: 3.405

2.  Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.

Authors:  Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Sabine Fallscheer; Matthias Leschke; Jörn Sträter; Robert Eckert
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

3.  Patients with a Previous History of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics and Radiologic Findings.

Authors:  Darragh F Halpenny; Jane D Cunningham; Niamh M Long; Ramon E Sosa; Michelle S Ginsberg
Journal:  J Thorac Oncol       Date:  2016-05-17       Impact factor: 15.609

4.  Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.

Authors:  Shenhai Wei; Jintao Tian; Xiaoping Song; Bingqun Wu; Limin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-04       Impact factor: 4.553

5.  Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?

Authors:  Elisabeth O'Dwyer; Darragh F Halpenny; Michelle S Ginsberg
Journal:  Eur Radiol       Date:  2020-07-29       Impact factor: 5.315

6.  Clinical outcome in lung cancer with a second malignancy: The time sequence matters.

Authors:  Ming-Shian Lu; Miao-Fen Chen; Yao-Kuang Huang; Hui-Ping Liu; Ying-Huang Tsai
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

7.  Second Primary Lung Cancer with Glottic Laryngeal Cancer as Index Tumor - A Case Report.

Authors:  Jamal Akhtar; Rakesh Bhargava; Mohammad Shameem; Saurabh K Singh; Ummul Baneen; Nafees Ahmad Khan; Jassem Hassan; Prakhar Sharma
Journal:  Case Rep Oncol       Date:  2010-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.